Biotech | August 06, 2024
Lupin completes successful Phase 3 trials for Lucentis biosimilar
The successful completion of the global Phase 3 trials paves the way to obtain marketing approval in the U.S. and EU
The successful completion of the global Phase 3 trials paves the way to obtain marketing approval in the U.S. and EU
Revolutionary technology will further boost OneSource’s scientific services offerings
Shivani Satish Wagh takes on the role of Joint Managing Director
Ursodeoxycholic acid or ursodiol is a naturally occurring bile acid that is used dissolve cholesterol gall stones
This product will be manufactured at Lupin’s Nagpur facility in India and will be supplied to low and middle-income countries
The revenue for the Q1FY25 came in at Rs 1,085.7 crore, up 16.6 per cent YoY
The New Drug Application (NDA) includes data from the Phase III studies OASIS 1, 2 and 3 - showing elinzanetant significantly reduced the frequency and severity of moderate to severe vasomotor symptoms over 12 weeks compared to placebo
BAV has revolutionized the animal vaccination industry with its ground-breaking delivery methods that prioritize quality, safety, and efficacy
Performed an autologous bone marrow transplant, using the patient’s own cells to reduce the chances of infection and rejection
The acquisition will further strengthen Barentz’ position in India creating a leading life science distribution platform
Subscribe To Our Newsletter & Stay Updated
